EYPT is down -69.49% to $4.50 as of 9:36 a.m. ET Monday, versus Friday's regular-session close of $14.75, during regular trading after a premarket halt. The primary catalyst is topline Phase 3 LUGANO data showing Duravyu missed its primary endpoint for change in best corrected visual acuity versus aflibercept in wet AMD.

WRAP is trading down -13.83% at $1.62 in Monday's regular session, extending a premarket slide from Friday's $1.88 close. The primary catalyst is a $12.0 million registered direct offering priced at $1.40 per share, a steep discount to Friday's close, fueling dilution concerns.

Upcoming Phase 2 data readouts and potential regulatory advancements for lead candidate ABCL635 represent major near-term catalysts in the vasomotor symptoms market. Strategic positioning through a proprietary AI-driven antibody discovery platform provides competitive differentiation in addressing complex targets and novel modalities.

AbCellera Biologics shares gained approximately 76% over the 30-day period through the latest available close, rising from $6.47 on July 17, 2026, to $11.38 on August 14, 2026. The decisive catalyst was positive Phase 2 data for ABCL635, an investigational antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause.

HeartFlow shares rose about 54.4% in the 30 days through the August 14, 2026 close, from $27.25 on July 15 to $42.08. The advance was led by second-quarter results: revenue of $64.1 million, up roughly 48% year over year, and an adjusted loss of $0.07 per share that beat consensus expectations for a wider loss.

Ondas Inc. ( ONDS ) last closed at $9.24, meaning a move to $20 would require a gain of more than 115% from recent levels. The selected stock price target of $20 sits slightly above the Wall Street consensus analyst price target of roughly $19 to $20 and below the highest Street target of $25.

Fastly shares climbed about 44.5% over the 30-day period through mid-August 2026, rising from a $20.72 close on July 17 to $29.93 on August 14. Second-quarter results were the central catalyst: revenue rose 23% year over year to $183.3 million, non-GAAP EPS reached $0.15, and management raised full-year guidance.

The central question is whether Fastly, Inc. (FSLY) can reach a stock price target of $40, roughly 34% above its most recent close of $29.93 and above its 52-week high of $34.82. The strongest bullish factors include accelerating revenue growth, AI-related traffic demand, improving margins, and raised full-year 2026 guidance following strong Q2 results.

ZETA shares advanced roughly 34% in the 30 days through the August 14 close, from $21.68 on July 17 to $29.05. The move accelerated after Q2 2026 results, as revenue rose 43.5% year over year to $442.8 million and the company swung to positive GAAP net income.

PATH shares climbed approximately 31.8% over the 30-day window, from a closing price of $12.15 on July 17, 2026, to $16.01 on August 14, 2026. The advance extends a broader recovery, with the stock up roughly 52% over the trailing three months after touching its 52-week low of $9.20 in mid-May.

Bending Spoons shares rose about 21.3% over the trailing 30-day window, from a $32.40 close on July 17, 2026, to $39.31 at the latest close on August 14, 2026. The advance was driven by the proposed Airtable acquisition, better-than-expected second-quarter results, and analyst price-target increases, partly offset by a sharp post-earnings pullback.

The $200 price target represents roughly 50% upside from Duolingo's current level near $133, a level widely referenced by sell-side analysts and independent research. Duolingo's deliberate pivot toward user growth over near-term monetization is the strongest bullish argument — management is targeting 100 million daily active users (DAUs) by 2028, roughly double the current 56.5 million.

Target in focus: The $30 level is the most widely discussed near-term stock price target for Figma, Inc. (NYSE: FIG) , about 18% above the most recent close of $25.42. Strongest bullish factors: Accelerating revenue growth, high customer retention, and early evidence that AI features are driving paid adoption rather than displacing the platform.

Usio, Inc. recently raised its full-year 2026 revenue growth guidance to 14-16%, citing strong first-half performance and new business opportunities in payment processing. The upcoming launch of the Usio Ion platform represents a potential margin catalyst, targeting significant daily payment volumes in the embedded finance space.

Selected price target: $15 per share, roughly 19.5% above RMAX’s latest close of $12.55. Strongest bullish factor: The pending acquisition by The Real Brokerage values RMAX at $13.80 per share in cash or stock, creating a transaction-driven anchor of interest.

Lead candidate INO-3107 for recurrent respiratory papillomatosis (RRP) faces a key FDA Prescription Drug User Fee Act (PDUFA) decision on October 30, 2026, under accelerated approval review, representing a potential near-term regulatory catalyst. Company maintains cash runway into late first quarter 2027 following recent equity financing, supporting operations through the anticipated regulatory outcome and potential commercial preparations.

Micron's latest available price of $972.78 is up 14.6% from the July 17, 2026 close of $848.95, returning the stock toward the $1,000 level after a sharp late-July pullback. The August 14 close of $971.66 is roughly 34% above the May 15 close of $724.66, though shares remain about 20% below the late-June peak near $1,213.

Humacyte shares fell approximately 11.3% in the 30 days ended August 14, 2026, based on available closing prices of $0.6816 on July 15 and $0.6048 on August 14. The decline sharpened after second-quarter results missed consensus revenue and EPS expectations, renewing concerns about SYMVESS commercialization and cash burn.

Selected price target: $5.00, roughly 81% above the recent closing price of $2.76. Strongest bullish factors: two consecutive quarters of positive GAAP net income, accelerating revenue growth, and momentum in the PayFac and ACH businesses.

Upcoming Q2 2026 earnings release on August 27 could provide updated visibility into comparable sales trends and margin progress from the multi-price assortment rollout. Net store expansion of approximately 325 locations in fiscal 2026, alongside ongoing optimization of underperforming units, represents a core medium-term growth driver.